science wire

ALTITUDE study involved patients with type 2 diabetes and renal impairment who are at high risk of cardiovascular and renal events Committee overseeing study identified higher adverse events when Ras

Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study Significant reduction in brain volume loss demonstrated, reinforcing strong efficacy benefit in key secondary endpoint Basel, December 15, 2011 - Novartis announced today new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis (RRMS) treated with Gilenya (fingolimod) had a statistically significant 48% reduction in annualized relapse rates (ARR) at 24 months compared to placebo.

Trial shows Exjade, an iron chelator, is significantly better than placebo at reducing liver iron concentration in patients with NTDT Non-transfusion-dependent thalassemia (NTDT) is a genetic blood disorder in which patients may accumulate excess iron in the body Data will serve as basis for first regulatory filings in US and Europe by year end Basel, December 13, 2011 - Results from THALASSA, the first pivotal placebo-controlled study examining

COMFORT-II data showed INC424 provided clinically relevant and statistically significant improvements in symptoms at all evaluations vs.

ENESTcmr data show 23% of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11% who continued on Glivec Three-year ENESTnd data show 32% of newly diagnosed patients on Tasigna reached deepest levels of molecular response measured versus 15% on Glivec ENESTnd study also shows significantly fewer patients progressed to advanced stages of CML with Tasigna after three years, compared to Glivec Basel, D

Longer-term BOLERO-2 data reveal treatment with everolimus combined with hormonal therapy improved time to disease progression to 7.4 versus 3.2 months with hormonal therapy alone These results presented at SABCS provide further evidence that everolimus may represent a major advance for women with ER+HER2- breast cancer Published in NEJM today are previously-reported positive results of BOLERO-2, which serve as the basis for first

TGR5 activation inhibits Atherosclerosis by reducing macrophage inflammation and lipid loading.

Tasigna Phase III trials in Ph+ CML including 36-month follow-up data in newly diagnosed patients Exjade pivotal study results investigating iron chelation in patients with non-transfusion-dependent

Pivotal phase III data showed significantly greater blood pressure reductions with Rasitrio compared to dual combinations of each of its individual components Up to 85 percent of patients may need mu

FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metas

A team of researchers has improved the muscle structure and stamina of mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach. If they weren't held back by the effect of a natural inhibitor, our muscles would be stronger, more powerful and better formed than they are in reality.

FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer The vismodegib application has been granted priority review Roche today announced that the U.S. F

Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis Chronic steroid use to treat the symptoms of systemic juvenil

Phase II data showed oral once daily DEB025 plus ribavirin provided viral clearance in almost half of genotype 2 and 3 patients with hepatitis C DEB025 targets host proteins required for hepatitis C virus replication, showing activity across genotypes and high barrier to resistance More than 170 million people worldwide suffer from hepatitis C, a serious liver disease that can lead to cirrhosis, liver cancer and in some cases death Basel, Novemb

Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis In three Phase II trials, AIN457 provided a substantial increase in skin clearance in patients with moderate-to-severe plaque psoriasis[1-3] AIN457, a fully human anti-IL17A monoclonal antibody, offers a novel mechanism of action that suppresses the underlying inflammation in psoriasis[1-3] Approximately 2% of the world's

Novartis drug Gilenya (fingolimod) has more than 20,000 patient-years of exposure and shows up to 71% reduction in annualized relapse rates in MS patients with highly active disease Analyses presented at 5 th Joint Triennial Congress of ECTRIMS and ACTRIMS showed relapse rate reductions were consistent among subgroups of fingolimod-treated patients that had highly active disease in pivotal clinical trials Fingolimod demonstrated reductions in ra

Studies show investigational once-daily NVA237 provides superior 24-hour bronchodilation and increases exercise endurance relative to placebo , Additional data show NVA237 significantly prolonged time to first moderate/ severe COPD exacerbation and reduced associated hospitalizations NVA237 submitted for EU approval under brand-name Seebri Breezhaler for treatment of chronic obstructive pulmonary disease (COPD) Basel , September 27, 2011 - Novar

Gilenya first high efficacy oral therapy approved in Japan for the prevention of relapse and delay of progression of physical disability in adults with multiple sclerosis (MS) Ilaris the first drug a

Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone Study shows everolimus significantly enhances benefit from hormonal therapy, representing important advance for women with postmenopausal ER+ breast cancer , Worldwide regulatory filings planned by the end of 2011 based on these data, marking the first submission for everolimus in breast cancer Ba

Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells PAH is a debilitating disease of the heart and lungs affecting up to 260,000 people worldwide leading to heart failure and death , Basel, September 25, 2011 - Novart

Study met primary endpoint of kidney tumor response rate with 42% of patients on everolimus experiencing a response versus 0% on placebo Kidney tumors are present in up to 80% of patients with tubero

Rasitrio combines the only approved direct renin inhibitor, Rasilez, with the calcium channel blocker amlodipine, and the diuretic hydrochlorothiazide (HCT) In Phase III data, Rasitrio demonstrated s

Pyrazinamide—Old TB Drug Finds New Target More than 60 years after the discovery of pyrazinamide (PZA), a drug that is a mainstay of combination therapy for tuberculosis (TB), researchers have finally uncovered a mechanism of action that is convincing and novel. Stewart Cole (UPCOL - Chair of Microbial Pathogenesis ) comment (Science Perspective) on resent finding by Shi et al.

ACZ885, which neutralizes key inflammatory driver interleukin-1 beta , provided significant symptom improvement vs.

Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.

Approval follows recent CHMP positive opinion based on Phase II study showing SEGA tumor reduction in patients with TSC Subependymal giant cell astrocytoma (SEGA) is a non-cancerous brain tumor that

Phase III trial showed Afinitor reduced risk of cancer progression by 65% vs.

The interactive BioCamp program engages students around scientific advances and entrepreneurial opportunities The eighth annual event brings 60 top university students from 24 countries and territori

Agency issues Complete Response letter requesting more data to support approval; Novartis will continue to work with the FDA on next steps Novartis remains committed to studying ACZ885 in inflammator

Phase III trial showed everolimus significantly delayed tumor growth in patients with advanced neuroendocrine tumors (NET) of pancreatic origin Everolimus represents a potentially new targeted approa

Novartis plans to ship over 30 million doses of Fluvirin vaccine to US customers for 2011-2012 season with sufficient supply to meet customer demand Early delivery allows for early vaccination of pri

Largest Phase III study in tuberous sclerosis complex (TSC) showed 35% of patients treated with everolimus had a 50% or greater reduction in SEGA volume versus 0% on placebo Subependymal giant cell a

Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth Postmenopausal ER+HER2- metastatic breast cancer patients whose disease has pro

Arcapta is the only once-daily long-acting beta 2 -agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPD Clinical studies with Arcapta showed sustained improvement in lung function; improvements were seen at 5-minutes after first dose Arcapta is approved with data demonstrating improvements in health-related quality of life COPD is a progressive and life-threatening lung disease that affects more th

Onbrez is the only once-daily long-acting beta 2 -agonist (LABA) approved in Japan for treatment of chronic obstructive pulmonary disease Clinical data show that Onbrez provides rapid and sustained i

GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p< 0.001) with comparable efficacy to open-label tiotropium at 12 weeks NVA237 shown to be well-tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) Phase III data support first regulatory submission for NVA237 by end of 2011 Basel, June 30, 2011 - Results from the pivotal Phase III GLOW2 clinical trial show that once-da

If approved, Votubia (everolimus) will be first medication in EU for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) CHMP opinion based on Phase II study o

Advisory committee strongly endorsed the efficacy of ACZ885 (canakinumab) Committee voted against approval of ACZ885 for proposed indication; potential identified for use in more narrow patient popul

Novartis AG holds groundbreaking ceremony with Minister of Economic Development of the Russian Federation, E. Nabiullina, Governor of Saint - Petersburg V. Matvienko, and Novartis AG CE

Submission includes data in more than 6,000 infants and toddlers worldwide Protecting infants is critical as they are at highest risk of contracting meningococcal disease Basel, June 16, 2011 - Novar

Pivotal study in more than 1,800 infants shows Bexsero induces robust immune response when given alone or with other routine vaccines in different vaccination schedules Meningococcal serogroup B disease has highest incidence in infants and young children and can lead to death within 24-48 hours of first symptoms Bexsero can help protect the majority of people at risk for infection, as data show the vaccine also induces robust immune response in

Lucentis (ranibizumab) is first anti-VEGF approved for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal clinical data show rapid and signif

Data show 66% recurrence-free survival and 92% overall survival at five years following three years of adjuvant therapy with Glivec in patients with resected KIT+ GIST First large Phase III clinical trial to demonstrate survival benefits of extended treatment with Glivec for three years compared to one year following surgery Important finding for treatment of GIST patients who are at risk of recurrence following complete resection of primary tum

Myelofibrosis is a life-threatening blood cancer characterized by bone marrow failure, enlarged spleen and debilitating symptoms, including fatigue and pain Phase III trial (COMFORT-II) demonstrated INC424 significantly reduced enlarged spleen size, a major characteristic of the disease, when compared to best available therapy at 48 weeks A separate Phase III trial (COMFORT-I) of INC424 showed significant spleen size reduction and symptom improv

Plenary presentation of Phase III study examining benefit of extended adjuvant treatment with Glivec for three years vs.

Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate , Gouty arthritis, commonly referred to as gout, is an inflammatory disease affecting 1-4% of adults, causing severe pain and long-term consequences - Regulatory filings for the use of ACZ885 in gouty arthritis patients with limited treatment options have been submitted in the EU, US, Canada an

Patanol is the world's leading prescription eye drop used to treat the signs and symptoms of allergic conjunctivitis US court decision is an important milestone to defend Alcon's intellectual propert

Basel, May 18, 2011 - Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc. The segmental consolidated income statement data has been amended to reflect the new divisional structure following the Alcon merger. The new reporting structure will be effective from the second quarter of 2011.

Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV 1 ) by up to 230 mL from baseline Results add to comprehensive data supporting Onbrez Breezhaler as an effective treatment for COPD with good safety profile Basel, May 15, 2011 - Results of two Phase III studies show that once-daily Onbrez Breezhaler (indacaterol) plus tiotropium produced a significantly greater improvement in lung